This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND
by Zacks Equity Research
RARE's IND for UX016, a novel sialic acid prodrug targeting GNEM, a rare muscle disease, gets accepted by the FDA. The first-in-human study is slated for H2'26.
CPRXPositive Net Change ANIPPositive Net Change RAREPositive Net Change INDVNegative Net Change
biotechs
UTHR Stock Rises 12.5% on Promising Data From TETON-1 Tyvaso Study
by Zacks Equity Research
United Therapeutics jumps 12.5% as phase III TETON-1 data show strong lung function gains for Tyvaso in IPF, paving the way for a potential FDA filing.
UTHRNegative Net Change CPRXPositive Net Change ANIPPositive Net Change INDVNegative Net Change
biotechs
Biogen Secures FDA Nod for Higher Dose of SMA Drug Spinraza
by Zacks Equity Research
BIIB gains after the FDA clears higher-dose Spinraza, with data showing improved motor function and potential to counter rising SMA competition.
NVSNegative Net Change BIIBNegative Net Change RHHBYPositive Net Change IONSPositive Net Change
biotechs medical pharmaceuticals
Will AbbVie's Oncology Drugs Aid Top Line in 2026?
by Sundeep Ganoria
ABBV's oncology lineup faces a 2026 sales dip despite rising contributions from newer drugs, as pricing pressure on Imbruvica weighs on growth.
AZNNegative Net Change PFENegative Net Change MRKNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
New Strong Buy Stocks for March 31st
by Zacks Equity Research
EFXT, CPRX, GEV, STRA and BP have been added to the Zacks Rank #1 (Strong Buy) List on March 31st, 2026.
BPPositive Net Change STRAPositive Net Change CPRXPositive Net Change EFXTNegative Net Change GEVNegative Net Change
biotechs oil-energy
Incyte Reports Strong 54-Week Data From Late-Stage Skin Disorder Study
by Zacks Equity Research
Incyte's povorcitinib shows sustained 54-week efficacy in HS, with strong response rates and safety profile, reinforcing its potential.
NVSNegative Net Change INCYNegative Net Change ANIPPositive Net Change ADMAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will Positive Camzyos Data Strengthen BMY's Cardiovascular Portfolio?
by Ekta Bagri
BMY's Camzyos shows strong late-stage results in adolescent heart disease, boosting hopes for expanded use as cardiovascular portfolio faces mixed developments.
BMYNegative Net Change JNJNegative Net Change PFENegative Net Change CYTKNegative Net Change
biotechnology biotechs medical pharmaceuticals
RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease
by Zacks Equity Research
Rocket Pharmaceuticals drops despite the FDA's accelerated approval of gene therapy Kresladi in severe leukocyte adhesion deficiency-I, an ultra-rare disease.
PRTAPositive Net Change ANIPPositive Net Change RCKTNegative Net Change REPLPositive Net Change
biotechs
AZN Stock Gains as COPD Drug Clears Two Late-Stage Studies
by Zacks Equity Research
AstraZeneca jumps as tozorakimab hits primary goals in two phase III COPD trials, cuts exacerbations and shows promise in a disease with limited options.
REGNNegative Net Change SNYNegative Net Change AZNNegative Net Change RHHBYPositive Net Change
biotechs medical pharmaceuticals
Novartis Bolsters Immunology Pipeline With Excellergy Deal
by Zacks Equity Research
Novartis targets IgE-driven diseases with Excellergy buy, adding a phase I anti-IgE asset to boost its immunology pipeline and allergy franchise.
NVSNegative Net Change ANIPPositive Net Change ADMAPositive Net Change LQDANegative Net Change
biotechnology biotechs medical pharmaceuticals